GRFS or NBIX: Which Is the Better Value Stock Right Now?
GRFS vs. NBIX: Which Stock Is the Better Value Option?
Zacks·21d ago
More News
Xenon Q2 Loss Wider Than Expected, Pipeline Development in Focus
XENE's wider Q2 loss highlights its push toward late-stage epilepsy, depression, and bipolar disorder studies with azetukalner.
Zacks·29d ago
Here's What Key Metrics Tell Us About Neurocrine (NBIX) Q2 Earnings
Although the revenue and EPS for Neurocrine (NBIX) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks·1mo ago
Neurocrine Biosciences (NBIX) Q2 Earnings and Revenues Beat Estimates
Neurocrine (NBIX) delivered earnings and revenue surprises of +8.16% and +5.72%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
CPRX vs. NBIX: Which Stock Should Value Investors Buy Now?
CPRX vs. NBIX: Which Stock Is the Better Value Option?
Zacks·1mo ago
Indivior PLC (INDV) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Indivior (INDV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·2mo ago
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Neurocrine (NBIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·2mo ago
EGO or AEM: Which Is the Better Value Stock Right Now?
Zacks·3mo ago
CPRX vs. NBIX: Which Stock Is the Better Value Option?
Zacks·3mo ago
Should You Invest in the SPDR S&P Biotech ETF (XBI)?